Xerostomia (dry mouth) may be a side-effect of medication. It is also caused by irradiation of the head and neck region or by damage to or disease of the salivary glands. Patients with a persistently dry mouth may develop a burning or scalded sensation and have poor oral hygiene. They are prone to increased dental caries, periodontal disease, intolerance of dentures and oral infections, particularly candidiasis. Where possible, treatment is directed at the underlying cause of dry mouth. If this is not possible, or is only partially successful, symptomatic treatment is used.
The diagnosis of xerostomia is usually based on a quantitative assessment of unstimulated and stimulated whole saliva. However, there is a wide variation in the amount of saliva produced by individuals and work is ongoing to devise more accurate methods of assessing salivary gland function.
- Add notes to any clinical page and create a reflective diary
- Automatically track and log every page you have viewed
- Print and export a summary to use in your appraisal
Treating the underlying cause
- Drugs are a common cause of dry mouth. Reduce the dose or change the drug if possible. Morphine is a common but often overlooked cause of dry mouth. Other drugs that cause dry mouth include tricyclic antidepressants, antihistamines, antimuscarinic drugs, anti-epileptic drugs, antipsychotics, beta-blockers and diuretics.
- Dehydration should be treated.
- Simple measures will often relieve symptoms of dry mouth, even if rehydration is not undertaken.
- Anxiety can also cause dry mouth.
- Sjögren's syndrome - check antinuclear antibody titre.
Simple measures should be used by all patients. Dry mouth may be relieved in many patients by:
- Frequent sips of cool drinks.
- Sucking pieces of ice.
- Sucking sugar-free fruit pastilles.
- Eating partly frozen melon or pineapple chunks.
- Sugar-free chewing gum - which stimulates salivation in patients with residual salivary function.
- Petroleum jelly - which can be applied to the lips to prevent drying and cracking.
A Cochrane review found that there is no strong evidence that any topical preparation is better than simple measures for the treatment of xerostomia.Nevertheless, artificial saliva is frequently used and may help to relieve symptoms in some patients. A properly balanced artificial saliva should be of a neutral pH and contain electrolytes (including fluoride) to correspond approximately to the composition of saliva.
- Biotène Oralbalance® gel and Xerotin® oral spray are both artificial saliva preparations which have Advisory Committee on Borderline Substances (ACBS) approval for the treatment of any patient complaining of dry mouth.
- BioXtra® gel, Glandosane® aerosol spray, Saliva Orthana® spray or lozenges and Saliveze® oral spray are artificial saliva preparations which have ACBS approval only for patients whose dry mouth is secondary to radiotherapy or sicca syndrome.
These act by local stimulation of the salivary glands and are most effective in patients who have some residual salivary gland function.
- Salivix® pastilles, which act locally as salivary stimulants, are also available and have ACBS approval only for patients whose dry mouth is secondary to radiotherapy or sicca syndrome.
- SST® tablets may be prescribed for dry mouth in patients with salivary gland impairment and patent salivary ducts.
- Sugar-free chewing gum is as effective as artificial salivas.
Long-term use of acidic products may demineralise tooth enamel. Glandosane® spray, Salivix® pastilles and SST® tablets are acidic products.
- Irradiation for head and neck cancers.
- Dry mouth and dry eyes (xerophthalmia) in Sjögren's syndrome.
It can be considered for difficult cases.
- Most patients with drug-induced dry mouth usually respond to treatment after the first dose. In one study of tramadol-induced dryness, saliva production peaked 30-45 minutes after administration of pilocarpine.
- Pilocarpine is effective only in patients who have some residual salivary gland function. If there is no response it should be discontinued.
- Adverse effects include a risk of increased urethral smooth muscle tone and renal colic. Other side-effects include blurred vision and dizziness. This may affect performance of skilled tasks - eg, driving, particularly at night or in reduced lighting.
- Adequate fluid intake should be maintained to avoid dehydration associated with excessive sweating.
- Radiotherapy-induced dry mouth does not respond well to pilocarpine. One study showed that salivary gland transfer was four times more effective in this type of patient.
- Acupuncture has been found useful in the prevention of xerostomia when administered concurrently with radiotherapy.
- A technique called acupuncture-like transelectrical nerve stimulation is currently being investigated.
Surgical transfer of one submandibular gland to the submental space facilitates shielding of the gland during postoperative radiation therapy. Studies confirm that there is no adverse effect on the function of the gland in this position.
Further reading & references
- Dry mouth website
- Multi-disciplinary Guidelines for the Oral Management of Patients following Oncology Treatment, Royal College of Surgeons of England and The British Society for Disability and Oral Health (2012)
- Matsuzaki T, Susa T, Shimizu K, et al; Function of the membrane water channel aquaporin-5 in the salivary gland. Acta Histochem Cytochem. 2012 Oct 31;45(5):251-9. doi: 10.1267/ahc.12018. Epub 2012 Sep 22.
- Jeong SY, Kim HW, Lee SW, et al; Salivary Gland Function Five Years after a Radioiodine Ablation in Patients with Differentiated Thyroid Cancer: Direct Comparison of Pre and Post-Ablation Scintigraphies and Their Relation to Xerostomia Symptoms. Thyroid. 2012 Nov 15.
- Palliative cancer care - oral; NICE CKS, November 2012
- Liu B, Dion MR, Jurasic MM, et al; Xerostomia and salivary hypofunction in vulnerable elders: prevalence and etiology. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Jul;114(1):52-60. doi: 10.1016/j.oooo.2011.11.014. Epub 2012 May 4.
- Busato IM, Ignacio SA, Brancher JA, et al; Impact of clinical status and salivary conditions on xerostomia and oral health-related quality of life of adolescents with type 1 diabetes mellitus. Community Dent Oral Epidemiol. 2012 Feb;40(1):62-9. doi: 10.1111/j.1600-0528.2011.00635.x. Epub 2011 Aug 25.
- Diogo Lofgren C, Wickstrom C, Sonesson M, et al; A systematic review of methods to diagnose oral dryness and salivary gland function. BMC Oral Health. 2012 Aug 8;12(1):29.
- Turner MD, Ship JA; Dry mouth and its effects on the oral health of elderly people. J Am Dent Assoc. 2007 Sep;138 Suppl:15S-20S.
- Nonzee V, Manopatanakul S, Khovidhunkit SO; Xerostomia, hyposalivation and oral microbiota in patients using antihypertensive medications. J Med Assoc Thai. 2012 Jan;95(1):96-104.
- British National Formulary (links to latest edition)
- Furness S, Worthington HV, Bryan G, et al; Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD008934.
- Taylor SE; Efficacy and economic evaluation of pilocarpine in treating radiation-induced xerostomia. Expert Opin Pharmacother. 2003 Sep;4(9):1489-97.
- Looström H et al; Tramadol-induced oral dryness and pilocarpine treatment: Effects on total protein and IgA, Arch Oral Biol. 2011 Apr;56(4):395-400.
- Meng Z, Garcia MK, Hu C, et al; Randomized controlled trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. Cancer. 2012 Jul 1;118(13):3337-44. doi: 10.1002/cncr.26550. Epub 2011 Nov 9.
- Wong RK, James JL, Sagar S, et al; Phase 2 results from Radiation Therapy Oncology Group Study 0537: a phase 2/3 study comparing acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating early radiation-induced xerostomia. Cancer. 2012 Sep 1;118(17):4244-52. doi: 10.1002/cncr.27382. Epub 2012 Jan 17.
- Jha N, Harris J, Seikaly H, et al; A phase II study of submandibular gland transfer prior to radiation for prevention of radiation-induced xerostomia in head-and-neck cancer (RTOG 0244). Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):437-42. doi: 10.1016/j.ijrobp.2012.02.034. Epub 2012 Apr 27.
|Original Author: Dr Richard Draper||Current Version: Dr Laurence Knott||Peer Reviewer: Prof Cathy Jackson|
|Last Checked: 14/01/2013||Document ID: 319 Version: 3||© EMIS|
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.